Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.38 USD
Change Today -0.14 / -2.15%
Volume 531.9K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM

Progenics Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment Charges for the Fourth Quarter of 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company reported Fourth quarter revenue resulted in a loss of $0.6 million, primarily from RELISTOR royalty losses due to Salix's plan to accelerate the reduction of wholesaler inventory levels and substantially cease all sales efforts to wholesalers in the fourth quarter of 2014. This compares to revenues of $3.0 million due to RELISTOR royalty income in the fourth quarter of 2013. Operating loss was $12,954,000 against $8,923,000 a year ago. Net loss before income tax benefit was $12,940,000 against $8,913,000 a year ago. Net loss was $12,179,000 or $0.18 per basic and diluted share against $8,551,000 or $0.14 per basic and diluted share a year ago. For the year, the company reported total revenue of $44,377,000 against $7,862,000 a year ago. Operating income was $3,370,000 against operating loss of $42,980,000 a year ago. Net income before income tax benefit was $3,421,000 against net loss before income tax benefit of $42,934,000 a year ago. Net income was $4,410,000 or $0.06 per basic and diluted share against net loss of $42,572,000 or $0.76 per basic and diluted share a year ago. Full year 2014 revenue was up from the prior year, reflecting an increase in collaboration revenue, primarily resulting from the recognition of milestone from Salix, partially offset by decrease in RELISTOR royalty income, compared to 2013. For the quarter, the company reported intangible impairment charges of $2,100,000.

Progenics Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 16, 2015

Progenics Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 16, 2015

Progenics Pharmaceuticals Presents Positive Phase 2 Data for PSMA

Progenics Pharmaceuticals, Inc. announced full results from its Phase 2 clinical study of PSMA ADC in patients with metastatic castration-resistant prostate cancer (mCRPC), including new data from the recently completed chemo-na ve cohort. The data was presented in a poster session and was also selected for inclusion in the ASCO GU Audio Poster Tour at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, taking place from February 26 28, 2015 in Orlando, Florida. The Phase 2 trial assessed the anti-tumor activity and tolerability of PSMA ADC, an antibody drug conjugate, in both taxane-experienced and chemo-na ve patients that had progressed following treatment with abiraterone and/or enzalutamide. In the chemo-na ve cohort, treatment with PSMA ADC reduced tumor size and levels of PSA and CTCs (circulating tumor cells) evidencing strong anti-tumor activity. Among these chemo-na ve patients, one (3%) had a complete radiological response, four (14%) had a partial radiological response, 22 (76%) showed stable disease, and two (7%) experienced progressive disease. The study enrolled 119 patients with mCRPC that had progressed following treatment with abiraterone and/or enzalutamide, including 84 taxane-experienced patients and 35 chemo-na ve patients. Patients in the trial received PSMA ADC 2.5mg/kg or 2.3 mg/kg intravenously three times weekly for up to 8 cycles. Safety, antitumor activity, and exploratory biomarkers were assessed.

Progenics Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 02:05 PM

Progenics Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 02:05 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $6.38 USD -0.14

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $19.47 USD -0.01
CTI BioPharma Corp $1.82 USD -0.09
Inovio Pharmaceuticals Inc $10.04 USD -0.285
Peregrine Pharmaceuticals Inc $1.39 USD -0.04
Rigel Pharmaceuticals Inc $4.09 USD -0.08
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 98.7x
Price/Sales 10.0x
Price/Book 3.6x
Price/Cash Flow 89.7x
TEV/Sales 7.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.